Sonoma Pharmaceuticals (NASDAQ: SNOA) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitabiliy.
This is a summary of recent recommendations and price targets for Sonoma Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sonoma Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 49.25%. Alexion Pharmaceuticals has a consensus price target of $162.14, indicating a potential upside of 39.59%. Given Sonoma Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Sonoma Pharmaceuticals is more favorable than Alexion Pharmaceuticals.
Volatility and Risk
Sonoma Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.
Institutional and Insider Ownership
11.9% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 94.4% of Alexion Pharmaceuticals shares are held by institutional investors. 7.7% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Sonoma Pharmaceuticals and Alexion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Sonoma Pharmaceuticals and Alexion Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sonoma Pharmaceuticals||$12.82 million||2.24||-$8.47 million||$2.20||3.05|
|Alexion Pharmaceuticals||$3.25 billion||8.03||$1.26 billion||$2.09||55.58|
Alexion Pharmaceuticals has higher revenue and earnings than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alexion Pharmaceuticals beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.